< Back to the list of products
Carprogesic 20 mg tablets for dogs
Carprogesic 50 mg tablets for dogs
Carprogesic 100 mg tablets for dogs
- Contains carprofen, a non-steroidal anti-inflammatory drug (NSAID) for oral administration in dogs, which selectively inhibits cyclooxygenase (COX)-2.
- Carprogesic tablets are indicated for analgesia and reduction of chronic inflammation, in musculoskeletal disturbances in dogs, for example in degenerative joint disease in dogs.
- Carprogesic expands the choice of cost-effective carprofen treatments.
- Available in white/off white circular tablets for oral administration in three strengths, 20mg, 50mg and 100 mg.
Description
Each tablet contains
| Active ingredient: | |
|---|---|
| Carprogesic 20 mg: | Carprofen 20 mg |
| Carprogesic 50 mg: | Carprofen 50 mg |
| Carprogesic 100 mg: | Carprofen 100 mg |
INDICATIONS
For analgesia and reduction of chronic inflammation, for example in degenerative joint disease, in dogs. Carprogesic 100 mg also as a follow up to parenteral analgesia in the management of post operative pain.
CONTRAINDICATIONS
Do not use in cats.
Do not use in pregnant or lactating bitches.
Do not use in puppies less than 4 months of age.
Do not use in case of hypersensitivity to active substance or to any of the excipients.
Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal
ulceration or bleeding, or where there is evidence of a blood dyscrasia.
ADVERSE REACTIONS
Typical undesirable effects associated with NSAIDs such as vomiting, soft faeces/diarrhea, faecal occult blood, loss of appetite and lethargy have been reported. These adverse reactions occur generally within the first treatment week and are in most cases transient and disappear following termination of the treatment but in very rare cases may be serious or fatal.
If adverse reactions occur, use of the product should be stopped and the advice of a veterinarian should be sought.
As with other NSAIDs there is a risk of rare renal or idiosyncratic hepatic adverse events.
TARGET SPECIES
Dogs
DOSAGE, ROUTE AND METHOD OF ADMINISTRATION
Carprogesic 20 and 50 mg:
For oral administration. An initial dose of 2 to 4 mg carprofen bodyweight/day is recommended to be given in two equally divided doses. The dose may be reduced to 2 mg carprofen/kg bodyweight/day administered as a single daily dose after 7 days, subject to clinical response. See maintenance dose table below.
| Maintenance Dose Table | Number of tablets per dose | |
|---|---|---|
| Bodyweight (kg) | 20 mg | 50 mg |
| 5 | 0.5 | - |
| 10 | 1 | - |
| 12.5 | - | 0.5 |
| 15 | 1.5 | - |
| 20 | 2 | - |
| 25 | - | 1 |
| 37.5 | - | 1.5 |
| 50 | - | 2 |
Carprogesic 100 mg:
For oral administration.
4mg carprofen per kg bodyweight per day.
An initial dose of 4 mg carprofen per kg bodyweight per day given as a single daily dose or in two equally divided doses. The daily dose may be reduced, subject to clinical response.
Do not exceed the stated dose.
To extend analgesic and anti-inflammatory cover post-operatively parenteral pre-operative treatment with an injectable Carprofen product may be followed with Carprogesic 100 mg Tablets at 4mg/kg/day for up to 5 days.
Return any halved tablets to the blister pack and use within 48 hours.
Duration of treatment:
Duration of treatments will be dependent upon the response seen. Long term treatment should be under regular veterinary supervision.
WITHDRAWAL PERIOD
Not applicable
SHELF LIFE
Shelf-life of the veterinary medicinal product as packaged for sale:
Blister packs: 2 years
Polypropylene tubs (Carprogesic 20 mg and 50 mg): 3 years
SPECIAL STORAGE PRECAUTIONS
Do not store above 25°C.
Store in a dry place and protect from light.
SPECIAL WARNINGS
Special precautions for use in animals
Use in dogs less than 6 weeks of age, or in aged animals, may involve additional risk. If such use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of increased renal toxicity.
Concurrent administration of potential nephrotoxic drugs should be avoided.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.
Do not exceed the stated dose. There is no specific antidote for carprofen overdosage but general supportive therapy, as applied to clinical overdosage with NSAIDs should be applied.
Special precautions to be taken by the person administering the product
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
OTHER INFORMATION
ATC vet code: QM01AE91
Nature and composition of immediate packaging
Polypropylene tubs with white polyethylene snap secure caps.
Aluminium-Aluminium blister strips.
20 mg tablets:
Box of 10 blister strips, each strip contains 10 tablets.
Tub containing 100 tablets.
50 mg tablets:
Box of 10 blister strips, each strip contains 10 tablets.
Box of 50 blister strips, each strip contains 10 tablets.
Tub containing 100 tablets.
Tub containing 500 tablets.
100 mg tablets:
Blister strips of 10 tablets in cartons containing 10, 20, 30, 50, 60, 70, 100, 140, 180, 200, 250, 280, 300, 500 or 1000 tablets.
Tubs containing 14, 30 or 100 tablets
National label conditions must be observed by country.
Marketing Authorisation Holder:
Norbrook Laboratories Limited
Stantion Works
Camlough Road, Newry
Co. Down, BT35 6JP
Northern Ireland
